Irina Zharkikh

Mrs. Irina Zharkikh

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
VSVictoria Skurikhina
Victoria Skurikhina
EPEdgar Pan
Edgar Pan
MZMariia Zhukova
Mariia Zhukova
IZIrina Zharkikh
Irina Zharkikh
ADAlexander Dygai
Alexander Dygai
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.

9 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
VSVictoria Skurikhina
Victoria Skurikhina
EPEdgar Pan
Edgar Pan
MZMariia Zhukova
Mariia Zhukova
IZIrina Zharkikh
Irina Zharkikh
ADAlexander Dygai
Alexander Dygai
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.

13 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
EPEdgar Pan
Edgar Pan
VSVictoria Skurikhina
Victoria Skurikhina
VPValentina Pan
Valentina Pan
IZIrina Zharkikh
Irina Zharkikh
ESEvgenii Skurikhin
Evgenii Skurikhin
Background: Reserpine’s effect on sympathetic regulation of inflammatory cell mobilization and migration reduces neuroinflammation after traumatic brain injury (TBI). We hypothesize that an important consequence of reserpine effect may be the acceleration of brain regenerative processes. Methods: Neuroinflammation and the response of neuronal cells and neural stem cells in the cerebral cortex (CC) and subventricular zone (SVZ) of ICR mice after TBI and reserpine treatment were assessed using histological and immunohistochemical methods. Results: TBI was accompanied by neuroinflammation, cellular and tissue degeneration, neuronal cell damage, and impaired proliferation of neural stem cells in CC and SVZ. Reserpine administration inhibited neuroinflammation and reduced the severity of degenerative processes. Furthermore, an increase in the number of neural stem cells and neuronal cells was observed in the CC and SVZ. Conclusions: Reserpine is a promising compound for developing a new approach to TBI therapy aimed at blocking the sympathetic pathway of neuroinflammation and degeneration. This results in accelerated neuronal cell regeneration.